Evolution of the Average Target: Supernus Pharmaceuticals, Inc.

Evolution of the Average Target - Supernus Pharmaceuticals, Inc.

Evolution of the Target Price: Supernus Pharmaceuticals, Inc.

Evolution of the Target Price - Supernus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Supernus Pharmaceuticals, Inc.

d50267298167bd1bed44053bde2f4a.nemRYNZqsJ-p8LjDpMHj0aBXXQP8W9ZFFsyTeIEmoWw.1pCjGZhf2_3as4y55aLRkNMEMWGOMJssI5z_MdNvwC-lk8cRsjXp0-jJgA~36b7af8494ce6c12d996a027c4c4e6fc
01-07 Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says MT
25-10-29 BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target MT
25-10-09 Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade MT
25-10-09 Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 MT
25-07-30 Supernus Shares Rise After Upgrade From Cantor Fitzgerald MT
25-07-30 Cantor Fitzgerald Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $42 From $36 MT
25-06-16 Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral MT
25-02-19 Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 MT
25-01-06 Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target MT
24-02-28 Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating MT
23-05-10 Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $46 From $45, Keeps Overweight Rating MT
23-01-23 Piper Sandler Adjusts Supernus Pharmaceuticals Price Target to $47 From $40, Maintains Overweight Rating MT
22-08-31 Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating MT
21-12-01 Jefferies Reinstates Supernus Pharmaceuticals at Buy With $44 Price Target MT
21-04-13 Supernus Pharmaceuticals : Jefferies Lifts Supernus Pharmaceuticals to Buy From Hold, Price Target to $40 From $25 MT
21-02-03 Supernus Pharmaceuticals : Piper Sandler Adjusts Supernus Pharmaceuticals PT to $35 From $30, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+59.71%
+5.65%
+9.33%
-0.99%
-0.52%
+8.56%
-0.8%
+26.78%
-8.67%
+2.34%
Average +10.14%
Weighted average by Cap. +5.00%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
37.88USD
Average target price
60.50USD
Spread / Average Target
+59.71%
High Price Target
67.00USD
Spread / Highest target
+76.87%
Low Price Target
55.00USD
Spread / Lowest Target
+45.20%

Analyst Consensus Detail

Analyst consensus - Supernus Pharmaceuticals, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Supernus Pharmaceuticals, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SUPN Stock
  4. Consensus Supernus Pharmaceuticals, Inc.